EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation



Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation



Annals of Hematology: -




(PDF emailed within 0-6 h: $19.90)

Accession: 058368103

Download citation: RISBibTeXText

PMID: 27766393

DOI: 10.1007/s00277-016-2854-0



Related references

Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation. Pediatric Transplantation 19(6): 652-658, 2016

Mycophenolate mofetil as salvage treatment for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Safety analysis. Blood 90(10 SUPPL 1 PART 1): 105A, Nov 15, 1997

Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan. International Journal of Hematology 2019, 2019

Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation. Korean Journal of Internal Medicine 29(5): 630-636, 2015

Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database of Systematic Reviews 2015(7): Cd010280-Cd010280, 2015

Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases. Zhonghua Yi Xue Za Zhi 88(30): 2127-2130, 2009

Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease. Transplantation Proceedings 41(9): 3873-3876, 2010

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 24(3): 600-607, 2017

Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation. Pediatric Transplantation 16(7): 771-778, 2013

Human Herpesvirus 6 Encephalitis in Patients Administered Mycophenolate Mofetil as Prophylaxis for Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Infectious Disease 13024-E13024, 2018

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 104(4): 1224-1226, 2004

Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Plos One 10(8): E0136991-E0136991, 2016

CAMPATH-1H reduces the risk of graft versus host disease following allogeneic hematopoietic stem cell transplantation and minimally myelosuppressive conditioning treatment with low dose total body irradiation and Cyclosporine/Mycophenolate Mofetil immunosuppression. Blood 98(11 Part 2): 355b-356b, November 16, 2001

Basiliximab for the Treatment of Steroid Refractory Acute Graft-Versus-Host-Disease Following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 22(3): S476-S477, 2016

Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation. Annals of PharmacoTherapy 41(9): 1436-1444, 2007